tbuckley/cabot-search huggingface dataset:
Abstract 243: Differential effects of combination treatment of biochanin A and statins on glioblastoma multiforme cell proliferation and cell metabolism
Authors: Vilas S. Desai, Eric Buchhalter, Max Cabanzo, Arushi Tiwari, Gagan Kaushal, James C. Lai, Alok Bhushan
Journal: Cancer Research (2019)

Abstract Glioblastoma Multiforme (GBM) is a deadly brain cancer and represents the most common central nervous system (CNS) tumors in adults. Although GBM does not metastasize, its aggressive growth and invasive nature are responsible for poor patient prognosis. The current standard therapy for newly diagnosed GBM patients involves surgical resection, followed by radiation and chemotherapy with Temozolomide. However, its rapid rate of infiltration into normal brain tissue ultimately renders the therapy ineffective. Epidemiological studies on dietary isoflavones (e.g., genistein, biochanin A) have shown their anti-cancer potential in different cancers. Though primarily used in management of hyperlipidemia and cardiovascular diseases, statins are known to exert anti-proliferative effects. We therefore hypothesized that a combination treatment of biochanin A &amp; statins (e.g., Atorvastatin, Lovastatin, Simvastatin, Fluvastatin and Pravastatin) exerts enhanced anticancer effects on GBM U-87 MG and T98 G cells. Our studies showed statins induced differential effects on viability of GBM cells in combination with biochanin A, with U-87 MG being more susceptible than T98 G cells. The combination treatment of biochanin A and atorvastatin also decreased invasion in U-87 MG cells. Additionally, cell metabolism studies using seahorse XFp analyzer showed a switch in their metabolic phenotype with an increase in mitochondrial respiration and a decrease in glycolytic activity with the combination treatment. We also performed metabolite extraction on GBM cells for a global unbiased profiling of metabolites using a single extraction procedure and dual separation analysis by LCMS. A differential analysis of alternative GBM treatment indicated statistically significant changes in carbohydrate and amino acid metabolism as well as alterations to various degradation pathway intermediates. Together, the combination treatment-induced effects on GBM cell lines are differential and our results may have potential implications in developing combination therapies with biochanin A in vivo and support the design of new and better therapies for the treatment of a lethal cancer like GBM. Citation Format: Vilas S. Desai, Eric Buchhalter, Max Cabanzo, Arushi Tiwari, Gagan Kaushal, James C. Lai, Alok Bhushan. Differential effects of combination treatment of biochanin A and statins on glioblastoma multiforme cell proliferation and cell metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 243.
Postpartum hemolytic uremic syndrome. Late recovery after prolonged maintenance dialysis
Authors: A. R. Nissenson
Journal: JAMA (1979)

POSTPARTUM hemolytic uremic syndrome (HUS) is a condition of obscure origin with grave prognostic implications. Of the 40 cases described to date, 80% of the patients have died, and 15% have required maintenance dialysis or renal transplantation. Only 5% have recovered, and all of these showed improvement within one month.<sup>1</sup> We describe a patient with postpartum HUS and renal failure who recovered much later than previously reported, after more than a year of receiving maintenance dialysis. <h3>Report of a Case</h3> A 28-year-old woman (gravida 2, para 0) was admitted to the Prentice Women's Hospital at the 28th week of pregnancy because of mild hypertension and protein-uria. Her first pregnancy five years earlier was interrupted by a spontaneous abortion at 15 weeks. During the current pregnancy, she gained 11.4 kg during a seven-month period, and her blood pressure (BP) had increased from 110/60 to 150/70 mm Hg. Results of urinalysis
Correction
Journal: Annals of the Rheumatic Diseases (1968)

Phenformine (Dibotin) dans la polyarthrite RESUME On compara par la methode de "double-blind cross- over" la phenformine (Dibotin) a un placebo chez 20 malades atteints de polyarthrite rhumatoide active.On ne trouva qu'un seul effet statistiquement significatif: la reduction de la vitesse de sedimentation globulaire (VSG).Une legere amelioration de la force de la main chez les malades trait6s par la phenformine fut en dessous des limites de signification, mais le nombre des cas dans la serie fut petit.II serait possible que l'alteration de la VSG au cours du traitement par la phenformine ne soit pas un signe d'amelioration de la condition rhumatoide mais un resultat de l'action de ce produit sur le taux sanguin du fibrinogene.
TMOD-13. MAXIMIZING THE POWER OF PATIENT TUMOR-DERIVED ORTHOTOPIC XENOGRAFT (PDOX) MODELS OF PEDIATRIC BRAIN TUMORS TO PREDICT DRUG RESPONSES IN HUMANS
Authors: Sarah Injac, Yuchen Du, Mari Kogiso, Frank Braun, Huiyuan Zhang, Lin Qi, Holly Lindsay, Sibo Zhao, Xiao-nan Li
Journal: Neuro-Oncology (2019)

Brain tumors are the leading cause of cancer-related death in children. A major challenge in the development of new therapies is the failure of many model systems to accurately predict drug responses patients. We identified two major weakness common to the majority of available models of pediatric brain tumors. First, while patients receive multi-modal therapy, pre-clinical testing typically involves the comparison of single agent therapy to placebo or other single agents. Two, while the majority of early phase clinical trials are carried out in relapsed, frequently heavily pre-treated patients; pre-clinical models almost exclusively represent untreated disease. To begin to address these issues, our lab has leveraged our large panel (>80) orthotopic xenograft mouse models of brain tumors which have undergone extensive molecular characterization. We designed treatment schedules based on original patient treatment data for 8 pediatric glioblastoma models and 9 medulloblastoma models and treated them accordingly. We are able to demonstrate the feasibility of combining radiation and multi-agent cytotoxic chemotherapy our mouse models. Furthermore, our results correlate with what has been seen in large scale human clinical trials with glioblastoma and DIPG models showing little benefit from standard treatments while medulloblastoma models show a significant increase in survival time. Going forward, these survival data will provide a more appropriate basis for the comparison of novel compounds allowing for increased efficiency in translating promising new treatments. Furthermore by harvesting the tumors which progressed after being exposed to patient based therapies, we have generated a resource that will allow for the establishment of more accurate models of brain tumor relapse in the future.
Inhibition of cell growth of human hepatoma cell line (HEP G2) by a farnesyltransferase inhibitor: A selective suppression of RAS farnesylation 2nd Dept. of Int. Med., Osaka University Med. School, Osaka, Japan
Journal: Hepatology (1995)

This chapter reviews the genetic studies that have provided new information on the biochemical and medical importance of CAAX-protein prenylation. The CAAX proteins undergo three sequential posttranslational processing steps: prenylation, endoproteolysis, and carboxyl methylation. These steps are mediated by four different enzymes: farnesyltransferase (FTase) or geranylgeranyltransferase type I (GGTase-I), RAS converting enzyme 1 (RCE1), and isoprenylcysteine carboxyl methyltransferase (ICMT). Over the past 20 years, there has been an intense interest in understanding the biological significance of CAAX protein processing and its impact on CAAX protein stability, membrane targeting, protein–protein interactions, signaling, and function. The genetic studies with Fntb and Pggt1b conditional knockout alleles support the idea that farnesylation is essential for H-RAS membrane association and HDJ2 and prelamin A prenylation and that both farnesylation and geranylgeranylation are essential for fibroblast and keratinocyte proliferation in vitro. Knockout of Fntb alone and Pggt1b alone significantly impairs K-RAS-induced tumor growth in vivo despite the fact that K-RAS remains prenylated under both conditions. The results also support the idea that simultaneous inhibition of FTase and GGTase-I blocks K-RAS prenylation and could be therapeutically useful.
A prospective study of the outcome for fetuses with diaphragmatic hernia
Authors: M. R. Harrison
Journal: JAMA (1994)

<h3>Objective.</h3> —To establish the natural history and outcome of isolated congenital diaphragmatic hernia (CDH) diagnosed before birth. The mortality of CDH with currently available postnatal care, including extracorporeal membrane oxygenation (ECMO), reported in retrospective studies ranges from less than 25% to greater than 75%. This variation is attributable to a "hidden mortality" (infants who die with CDH that is not recognized) of unknown magnitude. <h3>Design.</h3> —Prospectively followed case series. <h3>Setting.</h3> —Patients were referred from practitioners in 18 states and evaluated and followed up by the University of California, San Francisco, Fetal Treatment Center. Arrangements were made for planned delivery at tertiary perinatal centers with ECMO capability. <h3>Patients.</h3> —All 83 fetuses with isolated, potentially correctable CDH diagnosed prior to 24 weeks' gestation referred to the University of California, San Francisco, Fetal Treatment Center between January 1989 and October 1993. <h3>Main Outcome Measures.</h3> —Survival beyond 2 months after optimal postnatal care. <h3>Results.</h3> —Fifty-eight percent (48 of 83) died despite optimal postnatal care (95% confidence interval, 41% to 75%). Of the 48 nonsurvivors, seven suffered intrauterine fetal demise, four were too premature for ECMO, 16 died before ECMO could be started, and 21 died despite ECMO therapy. Twenty-two of the 35 survivors received ECMO, and nine of these have severe chronic illness attributable to the intensive management. <h3>Conclusions.</h3> —In this study, the mortality for potentially correctable CDH diagnosed before 24 weeks' gestation is 58%, despite optimal care presently available after birth. Infants who die in utero and soon after birth constitute a substantial hidden mortality. (<i>JAMA</i>. 1994;271:382-384)
<i>Anaplasma phagocytophilum</i> induces actin phosphorylation to selectively regulate gene transcription in <i>Ixodes scapularis</i> ticks
Authors: Hameeda Sultana, Girish Neelakanta, Fred S. Kantor, Stephen E. Malawista, Durland Fish, Ruth R. Montgomery, Erol Fikrig
Journal: The Journal of Experimental Medicine (2011)
Mechanism of Skin Tumorigenesis by Contact Sensitizers: The Effect of the Corticosteroid Fluocinolone Acetonide on Inflammation and Tumor Induction by 2,4 Dinitro-1-Fluorobenzene in the Skin of the TG.AC (v-Ha-ras) Mouse
Authors: Roy E. Albert, John E. French, Robert Maronpot, Judson Spalding, Raymond Tennant
Journal: Environmental Health Perspectives (1996)

The effect of the corticosteroid fluocinolone acetonide (FA) on skin tumor induction and inflammation by the contact sensitizer dinitrofluorobenzene (DNFB) was examined. This study broadly relates to the question of whether contact sensitizers, as electrophilic chemicals that produce protein adduction, may constitute an environmental cancer hazard. The specific aim of this study was to evaluate the extent to which the immunogenic inflammatory response to DNFB, in contrast to DNFB cytotoxicity, might be responsible for tumor induction. Experiments were conducted on a transgenic (TG.AC) mouse, incorporating a mutated ras oncogene (v-Ha-ras) that responds rapidly and profusely with skin papillomas to tumor promoters as if it were genetically initiated. Various doses and patterns of DNFB and FA were applied to the skin in a 2-week period; DNFB was given four times and FA was given either with the DNFB or daily. The tumor response to DNFB was completed by 8 weeks from the first dose and was consistent with a dose-squared relationship. FA was not tumorigenic alone; when given with DNFB, it caused only a small reduction in inflammation and tumor yield. When given daily, FA increased ulcerative skin damage, inflammation, and the yield tumors. The results suggest that tumorigenesis by DNFB, in the high-dose short-term regimen used here, is mainly due to its cytotoxicity and not contact sensitization.
THE HEATED TERM.BLUE URINE.
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tiger
Authors: Eric Pfeiffer
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).
Authors: Dung T. Le, Andrea Wang-Gillam, Vincent J. Picozzi, Todd S. Crocenzi, Michael Morse, Herbert Zeh, Robert Lance Fine, Aimee Murphy, Justin Skoble, Ed Lemmens, Sandy Ferber, Allan Rosen, John J. Grous, Thomas Dubensky, Dirk G. Brockstedt, Elizabeth M. Jaffee
Journal: Journal of Clinical Oncology (2014)

TPS4159 Background: A heterologous prime-boost vaccination strategy using GVAX pancreas vaccine and CRS-207 is showing promise in patients with metastatic pancreatic adenocarcinoma (PDA). GVAX is composed of lethally-irradiated, allogeneic pancreatic cancer cells modified to express GM-CSF and induces a broad response against multiple tumor antigens. GVAX is given with low-dose cyclophosphamide (CY) to inhibit regulatory T cells. CRS-207 is live-attenuated Listeria monocytogenes engineered to express the tumor-associated antigen mesothelin. CRS-207 boosts responses against mesothelin and is unique in its capacity to stimulate both innate and adaptive immunity by activating T cells and NK cells. Results from a phase 2 study demonstrated the CY/GVAX plus CRS-207 combination improved overall survival (OS) compared to CY/GVAX alone (p-value<0.05; Le, GI ASCO 2014). Methods: This is a phase 2b study comparing CY/GVAX and CRS-207 to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic PDA. Subjects will be enrolled in two cohorts: 150 subjects into a primary cohort of patients with at least two prior treatment regimens for metastatic disease (3rd+ line) and 90 subjects into an exploratory cohort of patients with only one prior treatment regimen for metastatic disease (2nd line). Subjects will be randomized in a 1:1:1 ratio to receive either 2 doses of CY/GVAX and 4 doses of CRS-207 (Arm A), six doses of CRS-207 (Arm B) or physician’s choice of select single-agent chemotherapy (Arm C). The primary objective is to compare OS in the primary cohort between Arms A and C. Secondary/exploratory objectives include: comparison of OS in both primary and exploratory cohorts between all treatment arms, assessment of safety and clinical responses (tumor assessments and CA19-9 levels) and correlation of Lm- and mesothelin-specific T cell and other immunological responses with OS, progression-free survival and best overall response. (Sponsor: Aduro BioTech, Inc.). Clinical trial information: NCT02004262.
THE SLEEPING SICKNESS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CNS abnormalities after hyperbilirubinemia
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Caffeine Analgesia
Authors: Anthony R. Temple
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The article by Laska and co-workers<sup>1</sup>evaluating the effect on analgesia of caffeine added to aspirin, acetaminophen, and salicylamide suggests that caffeine has some adjunctive analgesic benefit. However, the authors failed to elaborate carefully on several methodological flaws that might negate their conclusions and on the relatively insignificant clinical benefit derived from the caffeine effect they describe. Among the methodological flaws that make any interpretation of these data difficult are (1) the pooling of 26 or 30 studies that requires rather heroic assumptions as to linearity, parallelism, and homogeneity of variance and slopes and, given the conditions described, makes it impossible to test the validity of the assumptions made<sup>2</sup>; (2) the erroneous assumption that a linear relationship exists over the entire dosage range of 217 to 2,000 mg, even though there is a recognized lack of analgesia at the low end of the dosages used
Twelve kidney donors
Authors: C. H. Fellner
Journal: JAMA (1968)

Twelve renal homotransplantation donors were interviewed in depth between five weeks and 18 months after surgery. Unexpected findings were (1) the decision-making process about donorship did not at all follow a pattern compatible with the concept of "informed consent" but occurred as an instantaneous, irrational response which subsequently was justified and maintained with the aid of a number of defensive techniques; and (2) the prevalent idea that the organ donor makes a major sacrifice without getting anything of significance in return was not true for our subjects who looked back upon it not as a disruptive, but as an integrative experience.
Error in Description of Race/Ethnicity
Journal: JAMA Network Open (2020)

Kristen M. Beavers, PhD; Rebecca H. Neiberg, MS; Stephen B. Kritchevsky, PhD; Barbara J. Nicklas, PhD; Dalane W. Kitzman, MD; Stephen P. Messier, PhD; W. Jack Rejeski, PhD; Jamy D. Ard, MD; Daniel P. Beavers, PhD
High Concordance of Bipolar I Disorder in a Nationwide Sample of Twins
Authors: Tuula Kieseppä
Journal: American Journal of Psychiatry (2004)

OBJECTIVE: The few studies of bipolar I disorder in twins have consistently emphasized the genetic contribution to disease liability. The authors report what appears to be the first twin study of bipolar I disorder involving a population-based twin sample, in which the diagnoses were made by using structured, personal interviews. METHOD: All Finnish same-sex twins (N=19,124) born from 1940 to 1957 were screened for a diagnosis of bipolar I disorder as recorded in the National Hospital Discharge Register between 1969 and 1991 or self-reported in surveys of the Finnish Twin Cohort in 1975, 1981, and 1990. Thirty-eight pairs were thereby identified and invited to participate in the study; the participation rate was 68%. Lifetime diagnoses were made by using the Structured Clinical Interview for DSM-IV. The authors calculated probandwise and pairwise concordances and correlations in liability and applied biometrical model fitting. RESULTS: The probandwise concordance rates were 0.43 (95% CI=0.10 to 0.82) for monozygotic twins and 0.06 (95% CI=0.00 to 0.27) for dizygotic twins. The correlations in liability were 0.85 and 0.41, respectively. The model with no familial transmission was rejected. The best-fitting model was the one in which genetic and specific environmental factors explained the variance in liability, with a heritability estimate of 0.93 (95% CI=0.69 to 1.00). CONCLUSIONS: The high heritability of bipolar disorder was demonstrated in a nationwide population-based twin sample assessed with structured personal interviews.